Allgenesis announces Phase 1b data showing AG-80308 providing improvements in dry eye patients
AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.
SOE 2023: Optic Neuropathy Versus Maculopathy
Nicholas Volpe, MD shares insights from his talk titled "Optic Neuropathy Versus Maculopathy" at the European Society of Ophthalmology Congress being held in Prague.
SOE 2023: A mixed method study of geographic atrophy
Dr Christiana Dinah discusses her SOE presentation, "Geographic Atrophy: A Mixed Method Study."
Researchers receive funds to create early test for diabetic peripheral neuropathy
Scientists hope to develop novel AI solutions for the prediction of DPN using corneal OCT images.
Breaking News: FDA approves perfluorohexyloctane ophthalmic solution for dry eye disease
According to Bausch + Lomb and Novaliq, MIEBO is the first prescription eye drop approved for dry eye disease that directly targets tear evaporation, based on consistent results from a pair of pivotal Phase 3 trials.
FDA approves Eyenovia's ophthalmic spray for mydriasis
The announcement represents the first FDA-approved, fixed-combination of tropicamide and phenylephrine for mydriasis, according to the company.
ARVO 2023: Lamina cribrosa pressure and predicting structural glaucoma progression
Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone, talks about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.
FDA approves Zeiss aspheric, monofocal, single-piece C-loop IOL
The company’s CT Lucia 621P monofocal IOL enables surgeons to treat a wide range of cataract patients while supporting optimised visual outcomes.
ARVO 2023: Early detection of diabetic retinopathy in underserved communities
Dr Edmund Arthur shares his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.
ARVO 2023: Predictive AI algorithms and data interpretation
Dr T.Y. Alvin Liu talks about predictive AI and its uses in ophthalmology and screening of the eyes at this year's ARVO meeting.
ARVO 2023: Analysis of vision loss from GATHER clinical program
Dr Carl Danzig, MD, FASRS, spoke at this year's ARVO meeting on the post hoc analysis for the GATHER trials regarding vision loss and patients receiving ACP 2/mg versus sham.
ARVO 2023: Visual function, imaging and artificial intelligence with Apellis
Dr Caroline Baumal talks about Apellis' presentations focusing on visual function, imaging and artificial intelligence at this year's ARVO meeting.
ARVO 2023: Insight into cell death with AMD
Dr Deborah Ferrington talks about her ARVO presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.
Researchers receive funding to continue work for sight loss breakthrough
A research team of scientists from a trio of European universities, led by a Northumbria University academic, has received funding to research age-related macular degeneration.
Alimera expands agreement with Horus Pharma to include marketing Iluvien in the Nordic countries
Horus will increase Iluvien’s commercial presence with Nordic retinal specialists.
COPHy 2023: Presence of macular neovascularisation on OCTA is predictive of subsequent exudation
Angela Carneiro, MD, PhD, discusses her position on a discussion titled Presence of Macular Neovascularization on OCTA is Predictive of Subsequent Exudation with David Hutton, Executive Editor, Ophthalmology Times®.
Large-scale study focuses on new insights into rare eye disorders
EMBL-EBI researchers use UK Biobank data to uncover new information about rare diseases of the eye.
Grifols enters into global collaboration and licensing agreement with Selagine to develop immunoglobulin eye drops to treat dry eye disease
Under the terms of the agreement, Grifols to have worldwide exclusive commercial rights to Selagine’s treatment upon regulatory authorization, expected in early 2029.
Angiogenesis: High-dose aflibercept demonstrates safety, efficacy in treatment of DME
David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.
APAO 2023: Looking at retinoblastoma in 2023
Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.
Angiogenesis 2023: Dry AMD and ellipsoid zone integrity
In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 conference, Justis Ehlers, MD, presented "Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint.”
Angiogenesis 2023: Clinical trial data from DERBY, OAKS for geographic atrophy
Rishi Singh, MD, presented data from the Phase 3 DERBY and OAKS clinical trials for geographic atrophy at the 2023 Angiogenesis, Exudation, and Degeneration conference.
US FDA approves to Ml6710i laser for use with Visudyne
According to a news release from Bausch + Lomb and biomedical laser company Modulight, the FDA has approved the ML6710i photodynamic laser for equivalent use with Visudyne.
Apellis submits marketing authorisation application to the European Medicines Agency for pegcetacoplan for geographic atrophy
Pegcetacoplan is the only GA treatment to demonstrate increased effects over 24 months across a broad patient population.
Re-Vana Therapeutics raises $11.9 million to advance ophthalmic technology platforms
The funding will give a boost to the development of the company's novel photo-crosslinked EyeLief, EyeLief-SD, and OcuLie biodegradable drug-delivery technologies.
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.
Trukera Medical rebranding ushers in new era of expansion into cornea market
Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
At AAO 2022, Dr Mitch Shultz provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.
Younger patients often require repeat corneal crosslinking, study finds
At the 2022 American Academy of Ophthalmology meeting, Dr Philip Dockery, MPH, presents, "Effectiveness of corneal crosslinking in young patients."
Investigators report positive visual outcomes one year after monocular implantation of small aperture IOL
Dr Mark H. Blecher dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."
2 Clarke Drive Cranbury, NJ 08512